Late relapse (>2 years) and strictly localized relapse of Ewing sarcoma were associated with better 5-year overall survival (29% vs 7% for late vs early relapse; 24% for local relapse, P<0.001).
Cohort (n=714)
Sí
In patients with relapsed Ewing sarcoma, overall survival is poor, though late onset (>2 years) and strictly localized relapse are favorable prognostic factors.
valor p: p=< 0.001
BACKGROUND: The prognosis in patients with relapsed Ewing sarcoma is unfavorable. Our investigation identifies factors predicting for the outcome following relapse. PROCEDURE: We analyzed type of relapse, time to relapse and overall survival after relapse (OSr) in 714 patients with first recurrence. All patients had been treated within the Cooperative Ewing Sarcoma Studies (CESS) 81 or 86, or the European Intergroup CESS (EICESS 92). OSr time was calculated from diagnosis of first relapse to last follow-up or death. RESULTS: Median follow-up time from diagnosis of primary disease was 2.2 years (mean = 4.0; range: 0.2-24.9). Relapse sites were local in 15%, combined local and systemic in 12%, and systemic in 73%. Among patients with a localized primary tumor, 20% relapsed locally, while 12% showed combined and 68% systemic relapse. When the primary disease was disseminated, 82% developed systemic, 13% combined, and 5% local relapse. Five-year OSr was 0.13 (SE = 0.01). Outcome following local relapse, with a 5-year survival rate of 0.24 (P 2 years) and strictly localized relapse.
Stahl et al. (Fri,) conducted a cohort in Relapsed Ewing sarcoma (n=714). Local relapse vs. Systemic or combined recurrence was evaluated on 5-year overall survival after relapse (OSr) (p=< 0.001). Late relapse (>2 years) and strictly localized relapse of Ewing sarcoma were associated with better 5-year overall survival (29% vs 7% for late vs early relapse; 24% for local relapse, P<0.001).